A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q)

Leukemia. 2013 Jul;27(7):1610-3. doi: 10.1038/leu.2013.59. Epub 2013 Feb 26.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptor Proteins, Signal Transducing
  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors / therapeutic use
  • Biomarkers, Tumor / genetics
  • Chromosome Deletion*
  • Humans
  • Lenalidomide
  • Middle Aged
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / genetics*
  • Peptide Hydrolases / genetics*
  • Polymorphism, Genetic / genetics*
  • Risk
  • Thalidomide / analogs & derivatives*
  • Thalidomide / therapeutic use
  • Ubiquitin-Protein Ligases

Substances

  • Adaptor Proteins, Signal Transducing
  • Angiogenesis Inhibitors
  • Biomarkers, Tumor
  • CRBN protein, human
  • Thalidomide
  • Ubiquitin-Protein Ligases
  • Peptide Hydrolases
  • Lenalidomide